Optimizing Patient Care in EGFR-Mutated NSCLC: AE Management and Supportive Care Strategies : Episode 2
Practical Adverse Management Strategies With Intravenous Amivantamab
Panelists discuss how venous thromboembolism risk assessment and prophylaxis decisions in patients with non–small cell lung cancer require careful consideration of individual risk factors, patient education strategies, and balanced communication about the benefits and concerns of preventive measures, particularly in the context of amivantamab therapy.
Video content above is prompted by the following:
- Shifting focus to cardiac adverse effects, specifically venous thromboembolism, or VTE, how do you approach risk assessment and prophylaxis in your practice?
- What factors do you consider when deciding on pharmacological vs nonpharmacological prophylaxis?
- What is your approach to VTE management with amivantamab?
- What strategies have you found effective in educating patients about early signs of VTE and the potential benefits of prophylaxis?
- In your experience, how do patients typically respond to discussions about VTE risk and potential prophylactic measures?
- In these conversations, how do you balance the potential benefits of prophylaxis with patient concerns about additional medications or injections?
Recent Videos
Related Content
